Reputation – General Public: Sector image Read more about the image of the pharmaceutical sector among the general public in the UK
The sector’s perceived lack of transparency is its main reputational weak spot, but less so than in previous years
To me, it's the curtains been pulled back here, they've opened up and then the pandemic's shut and then it’s closed again.
More transparency when there are issues, like particular drugs that have caused a problem and there's an investigation. The feeling always seems to be that they're resistant, not actually coming up with the information willingly
Last modified: 21 August 2023
Last reviewed: 21 August 2023